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Cryptococcus neoformans capsular polysaccharide is composed of at least two components, glucuronoxylo-
mannan (GXM) and galactoxylomannans (GalXM). Although GXM has been extensively studied, little is
known about the location of GalXM in the C. neoformans capsule, in part because there are no serological
reagents specific to this antigen. To circumvent the poor immunogenicity of GalXM, this antigen was conju-
gated to protective antigen from Bacillus anthracis as a protein carrier. The resulting conjugate elicited
antibodies that reacted with GalXM in mice and yielded an immune serum that proved useful for studying
GalXM in the polysaccharide capsule. In acapsular cells, immune serum localized GalXM to the cell wall. In
capsulated cells, immune serum localized GalXM to discrete pockets near the capsule edge. GalXM was
abundant on the nascent capsules of budding daughter cells. The constituent sugars of GalXM were found in
vesicle fractions consistent with vesicular transport for this polysaccharide. In addition, we generated a
single-chain fraction variable fragment antibody with specificity to oxidized carbohydrates that also produced
punctate immunofluorescence on encapsulated cells that partially colocalized with GalXM. The results are
interpreted to mean that GalXM is a transient component of the polysaccharide capsule of mature cells during
the process of secretion. Hence, the function of GalXM appears to be more consistent with that of an
exopolysaccharide than a structural component of the cryptococcal capsule.
Cryptococcus neoformans is an encapsulated fungal pathogen
that causes meningitis primarily in immunocompromised pa-
tients (22, 27). The incidence of cryptococcosis increased dra-
matically at the end of the 20th century in association with
advanced human immunodeficiency virus infection. Other
groups at risk are patients receiving immunosuppressive ther-
apies for cancers and transplants (3, 8). C. neoformans has
several well-defined virulence factors that include a polysac-
charide capsule. Classically, the capsular polysaccharide was
defined as being composed of glucuronoxylomannan (GXM),
galactoxylomannan (GalXM), and mannoproteins (MPs) (17,
25, 32). However, this composition has been assumed based on
analysis of exopolysaccharides. Although GXM has been ex-
tensively studied and is associated with many deleterious ef-
fects in the host, considerably less is known about GalXM.
There is no direct evidence for a structural role of GalXM and
MP in capsule assembly or architecture. In recent years, evi-
dence has emerged that GalXM is a more potent immuno-
modulatory molecule than GXM (9, 28). Percolini et al.
showed that GalXM inhibits T-cell proliferation and periph-
eral blood mononuclear cells. The study also revealed that
GalXM increased the production of the cytokines gamma in-
terferon and interleukin-10 (28). GalXM upregulates Fas and
initiates apoptosis of T lymphocytes by DNA fragmentation
through the activation of caspase 8 (28). GalXM also causes
apoptosis in macrophages through a FasL-related mechanism
(34).
GalXM constitutes about 8% of the shed polysaccharide
found in cryptococcal culture supernatants (3, 32) and has an
1,6-galactan backbone containing four potential short oligo-
saccharide branch structures. The branches are 3-O linked to
the backbone and consist of an 1,3-mannose, 1,4-mannose,
-galactosidase trisaccharide with variable amounts of 1,2- or
1,3-xylose side groups (3, 20, 32). The GalXM backbone
consists of galactopyranose and a small amount of galacto-
furanose (32), unlike GXM, which contains only mannopyr-
anose (3). The molar composition of GalXM components re-
vealed xylose at 22%, mannose at 29%, and galactose at 50%
(10, 32). Proton nuclear magnetic resonance (NMR) revealed
the anomeric region to be between 5.4 and 4.3 ppm in a
one-dimensional (1D) 1H spectrum recorded at 600 MHz and
56°C (10, 32). GalXMs from serotypes A, C, and D each
contain galactose, mannose, and xylose, but the molar ratios of
these sugars are not identical, suggesting structural variability.
GalXMs are thought to be a group of complex closely related
polysaccharides (16, 32).
GalXM, with an average mass of 1  105 Da (3, 20), is
significantly smaller than GXM (1.7  106 Da). Since GalXM
has a smaller molecular mass, GalXM is the most numerous
polysaccharide in shed capsular polysaccharide preparations
on a molar basis, with 2 to 3.5 mol of GalXM for each mol of
GXM (20).
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The location of GalXM in the C. neoformans capsule is
uncertain. In fact, it is not clear whether GalXM is a constit-
uent of the capsule or an exopolysaccharide. An attempt at
immunolocalization with the monoclonal antibody (MAb)
CN6, which is no longer available, suggested that GalXM was
located within the cytoplasm and the cell wall of the acapsular
mutant cap67 (16, 32). Given the usefulness of antibodies in
studying capsule (5, 13, 26), we have generated a serological
reagent for the localization of GalXM. The results suggest that
GalXM is a transient component of the capsule, is associated
with newly formed capsules, and may be present in vesicular
fractions.
MATERIALS AND METHODS
C. neoformans strains. Several strains of C. neoformans were used in this study:
24067 (serotype D), acapsular mutant cap67 and its parental strain B3501 (se-
rotype D), and NIH 34 (a serotype C reference strain typically used for the
production of rabbit anti-C serum) (29). NYC1343, a clinical isolate of serotype
C from New York (18), NIH 112, a serotype B strain (15), and serotype A/D
strain MAS92-203 were also tested. We also used strains KN99 (serotype A
parent strain of GalXM mutants), a ugt1 mutant (GalXM mutant in which the
UGT gene encodes a putative UDP-galactose transporter), and a uge1 mutant
(a GalXM mutant in which the UGE gene encodes a putative UDP-glucose
epimerase) (23). The uge1 strain was also constructed in the serotype D back-
ground of Jec21, and the strains were designated as follows: Jec21 (MAT),
NE570 (MAT uge1::NAT1), and NE571 MAT uge1::NAT1). To generate
the uge1 strain (serotype D), the disruption cassette for the gene UGE1 was
constructed by overlapping PCR as previously described (24). The primer se-
quences used are given in Table S1 in the supplemental material. The PCR-
amplified fragment was used to transform strain Jec21 by biolistic DNA delivery,
and transformants were selected on yeast extract-peptone-dextrose containing
100 g/ml of nourseothricin (Werner BioAgents). They were then screened for
homologous integration, first by PCR and then by Southern blotting, as previ-
ously described (24). Two mutant strains were isolated from two independent
transformations and stored at 80°C for further studies. The tagged plasmid
pNATSTM, used to amplify the selective marker, was kindly provided by Jen-
nifer Lodge (St. Louis, MO).
GXM and GalXM isolation. GXM was isolated as described by Cherniak et al.
(6). GalXM was isolated from the culture supernatant by the method described
in references 20 and 32. Briefly, a 400-ml culture of the C. neoformans acapsular
mutant of strain cap67 was grown in peptone supplemented with 2% galactose
for 7 days. The culture supernatant was separated from the cells by centrifuga-
tion at 900  g for 15 min at room temperature and then concentrated using an
Amicon centrifugal filter (Millipore, Bedford, MA) with a molecular-weight-
cutoff of 10,000. The material was then dialyzed for 1 week against distilled
water, and the 10-kDa retentate, containing GalXM and MPs, was passed
through a 0.2-m filter. The resulting filtrate was then lyophilized and stored at
room temperature. The freeze-dried mixture was dissolved in 25 ml start buffer:
0.01 M Tris base and 0.5 M NaCl solution (pH 7.2), to which CaCl2 and
Mn(II)Cl2 were sequentially added to final concentrations of 1 mM. To separate
the GalXM and MP, solution was then continuously passed through a con-
canavalin A (ConA)-Sepharose 4B column (2.5 by 10 cm) (Sigma) for 16 h at 4°C
using a peristaltic pump with a flow rate of 16 ml/h. The flowthrough and 11
column washes with start buffer were collected as 20-ml fractions (20). To
identify carbohydrate-containing fractions, we tested these using the phenol-
sulfuric acid assay (12). The fractions were combined, concentrated by ultrafil-
tration, and dialyzed against water for 7 days. GalXM was then recovered by
lyophilization. Compositional analysis of GalXM was done by combined gas
chromatography-mass spectrometry (GC-MS) of the per-O-trimethylsilyl deriv-
atives of the monosaccharide methyl glycosides produced from the sample by
acidic methanolysis (21). The possibility of ConA contamination was tested by
Western blotting with an anti-ConA antibody (Vector Laboratories, Burlingame,
CA). No ConA contamination was detected (not shown).
GalXM-Bacillus anthracis PA conjugate. GalXM hydroxyl groups were acti-
vated with cyanogen bromide (Sigma, St. Louis, MO). Briefly, GalXM (10 mg/ml
in 0.2 M NaCl) was activated with 10 mg/ml of cyanogen bromide with contin-
uous pH monitoring such that the pH was maintained between 10.5 and 11.0 for
6 min at 4°C. The activated GalXM was then derivatized with the bifunctional
linker adipic acid dihydrazide (ADH) (Sigma, St. Louis, MO). To do this, an
equal volume of 0.5 M NaHCO3 at pH 8.5 containing 0.5 M ADH was added to
the activated GalXM. The reaction mixture was then tumbled at 4°C for 18 h and
dialyzed against 0.2 M NaCl for 7 days. The reaction mixture containing GalXM-
ADH was then mixed with 5.0 mg/ml of protective antigen (PA) from Bacillus
anthracis (Wadsworth Laboratories, New York, NY) and brought to pH 5.6 with
0.05 N HCl and 0.05 M of the water-soluble carbodiimidine, 1-ethyl-3-(3 di-
methylaminopropyl)-carboiimide (EDAC) (Sigma, St.Louis, MO). The pH was
continuously maintained at 5.6 for 1 h at 4°C. The reaction mixture was then
dialyzed against 0.2 M NaCl for 24 h at 4°C (11). Bio-Rad Quick start protein
assay was used according to the manufacturer’s instructions to detect protein in
the conjugate.
Animals. Six- to 8-week-old BALB/c female mice were obtained from the
National Cancer Institute. Long Evans rats (body weight, 200 to 250 g) were
obtained from Charles River Laboratories (Wilmington, MA). All animal exper-
iments were done according to institutional guidelines.
Immunizations with GalXM. Mice and rats were given an intraperitoneal
immunization with 0.5, 5, 50, and 500 g of GalXM; saline; or 100 l of
GalXM-PA conjugate in complete Freund’s adjuvant. Mice were then boosted
with 0.1 g of GalXM or 50 l of the conjugate in incomplete Freund’s adjuvant
at day 14. The mice were bled, and serum titers were tested. Mice were sacrificed
by asphyxiation with CO2.
Serum antibodies. Blood was collected from mice, and serum was analyzed by
enzyme-linked immunosorbent assay (ELISA). Costar plates were coated with 50
g of GalXM, the plates were blocked with 2% bovine serum albumin (BSA) or
Superblock (Pierce, Rockford, IL), and a 1:100 dilution of serum was serially
diluted in a 1:3 ratio along the plate. A cocktail of alkaline phosphatase-conju-
gated anti-immunoglobulin M (IgM), -IgA, and -IgG (HL) polyclonal antibod-
ies (Southern Biotechnology, Birmingham, AL) at 1 g/ml was used as the
secondary antibody for the detection of bound antibodies. Reactions were de-
veloped with p-nitrophenyl phosphate (PNPP), and the absorbance was mea-
sured at 405 nm. BSA-coated plates were used as a negative control.
Biotinylated GXM and GalXM. GalXM (1 mg/ml) was oxidized with 20 mM
sodium periodate (Pierce, Rockford, IL) in dimethyl sulfoxide (DMSO) for 30
min at 4°C in the dark. To stop the oxidation reaction, 15 mM glycerol was added
to the mixture for 5 min at 4°C. The samples was then passed through Zeba
desalting columns (Pierce, Rockford, IL), previously equilibrated with 0.1 M
sodium acetate (pH 5.5). A 5 mM solution of biotin hydrazide was added to the
oxidized carbohydrate and incubated at room temperature for 2 h. To separate
the biotinylated carbohydrates from the unreacted biotin, the samples were again
passed through Zeba desalting columns. To test if GXM and GalXM had been
biotinylated, an ELISA was done by coating the plate with the biotinylated
sample by blocking with 1% BSA for 1 h. A 1:1,000 dilution of streptavidin
conjugated to alkaline phosphatase was used as the secondary reagent (Southern
Biotechnology, Birmingham, AL), and absorbance was measured at 405 nm after
development with PNPP.
Phage display peptide library screening. The phage display library was syn-
thesized with mRNA extracted from chickens immunized with fluorescein iso-
thiocyanate (FITC)-coupled BSA (1). The light and heavy chain variable regions
were amplified by reverse transcription-PCR, cloned into the pComb3X vector,
and transformed into Escherichia coli cells following protocols in reference 2.
The selection was made in four rounds: rounds 1 to 3 used biotinylated GalXM,
cap67 cells, and biotinylated GalXM, respectively. The 4th round was made
initially with intact cells, which yielded no phages. We then repeated this round
with biotinylated GalXM. Positive clones were selected by ELISA after the final
round of selection. These clones were sequenced, and the encoded single-chain
fragment variable regions (scFvs) were purified from cell lysates by affinity
chromatography in nickel-nitrilotriacetic acid columns (the vector encodes a
C-terminal His6 tag). GalXM-specific binding was assessed initially by ELISA
and then by immunofluorescence with uge1 and ugt1 mutants.
Panning with the antigens. Phage-biotinylated carbohydrate complexes were
captured by streptavidin-coated magnetic beads (Dynal Biotech, Lake Success,
NY). Beads were washed five times with 1 ml of Tris-buffered saline–Tween 20
(TBST) and pelleted using a magnetic rack each time. Antigen-specific phages
were eluted from the beads using 0.1 M glycine at pH 2.2 for 10 min at room
temperature. The eluate was then neutralized and transferred to 2 ml of XL-2
cells at an optical density at 600 nm (OD600) of 1 and incubated at room
temperature for 15 min.
Selection with intact cells. Because GalXM binds irregularly to ELISA plates,
we did the panning using biotinylated soluble antigen. To avoid selection of
irrelevant antibiotin or antistreptavidin bead phages, we decided to alternate
rounds of selection with whole cells. The reasoning was that the cells express
GalXM in their surface and would not select for the same irrelevant antibodies.
Since the two antigen forms could result in the isolation of antibodies with a
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different range of specificities, this design aimed to isolate scFvs which bind
GalXM in solution and in the surface of intact cells. Briefly, cap67 cells were
washed twice with TBST, counted and diluted in 1% BSA-TBS to108 cells/ml.
They were then incubated with the phage as with the beads above. Phage
precipitation and amplification was also done as described above. Input and
output titers were measured after each round of panning in ampicillin-supple-
mented LB (LB-AMP) plates.
Fluorescence microscopy. C. neoformans strains were grown in Sabouraud
dextrose broth (Difco Laboratories, Detroit, MI) for 3 days at 30°C. The cells
were washed three times with sterile phosphate-buffered saline (PBS [pH 7.4])
and then counted with a hemocytometer. Strains were normalized to a suspen-
sion of 2  106 cells/ml and incubated with a 1:100 dilution of GalXM-PA
polyclonal serum or nonimmune serum as a control in IF buffer (2% BSA and
0.05% goat serum in PBS). Cells were washed three times with IF buffer and
incubated with 4 g/ml of goat anti-mouse IgM-FITC. Alternatively, to deter-
mine cell age, cells were grown in Sabouraud dextrose broth for 2 days. The cell
wall was labeled first in a solution of 4-mg/ml EZ-Link sulfo-NHS-LC-biotin
[sulfosuccinimidyl-6-(biotinamido)hexanoate] in PBS (Pierce, Rockford, IL) for
30 min at room temperature at a cell density of 2  107 cells/ml. Cells were
extensively washed with PBS and then placed in the capsule-inducing medium for
2 days. Biotinylated cells were detected using 20 g/ml of streptavidin-Texas red
(Jackson Immunoresearch, West Grove, PA) (19). For staining with wheat germ
agglutinin (WGA), 106 yeast cells were suspended in 100 l of a 5-g/ml solution
of the Alexa Fluor 594 conjugate of WGA (Molecular Probes, Eugene, OR) and
incubated for 30 min at 37°C after incubation with GalXM-PA polyclonal serum
at same dilution as mentioned earlier (30). For staining with the lipophilic
carbocyanine dye Vybrant DiI (Molecular Probes, Eugene, OR), we used 1:100
dilution of GalXM-PA polyclonal serum for 1 h at room temperature and 1:100
goat anti-mouse (GAM)-IgM-FITC and 5 M Vybrant DiI overnight at 4°C.
Cells were suspended in mounting medium (50% glycerol and 50 mM N-propyl
gallate in PBS) and analyzed under an Olympus AX70 microscope. Images were
acquired using a QImaging Retiga 1300 digital camera and processed using
QCapture suite V2.46 software (QImaging, Burnaby, British Columbia, Canada).
Confocal microscopy. For GalXM staining using the GalXM-PA polyclonal
serum, 2  106 C. neoformans cells in 100 l of a buffer (2% BSA with 0.5% goat
serum) were incubated with 2 l of serum overnight at 4°C. The cells were
washed three times with buffer and incubated with 4 g/ml of anti-IgM–FITC as
the secondary antibody for 1 h at room temperature. For staining of C. neofor-
mans using the scFv, 2  106 cells in 100 l of IF buffer were incubated with 100
g/ml of the purified scFv clone D8 overnight at 4°C. The cells were washed
three times with buffer and incubated with a 1:100 dilution of antihemagglutinin
(anti-HA)-Alexa Fluor 488 as the secondary antibody for 1 h at room tempera-
ture. Stained cells were mounted on glass slides as described above and imaged
with a Leica SP2 laser scanning confocal microscope. 3D reconstructions of the
captured Z-stacks were made using ImageJ (NIH; http://rsb.info.nih.gov/ij/) and
Voxx (Indiana University; www.nephrology.iupui.edu/imaging/voxx/) software.
Vesicle isolation and carbohydrate analysis. Isolation of extracellular vesicles
was done using the protocol described by Rodrigues et al. (31). Briefly, cell-free
culture supernatants of cap67 cells were obtained by sequential centrifugation at
4,000 and 15,000  g (15 min at 4°C). These supernatants contained vesicles and
were concentrated by approximately 20-fold using an Amicon ultrafiltration
system (cutoff of 100 kDa). The concentrate was again centrifuged at 4,000 and
15,000  g (15 min at 4°C) for cell and debris removal and then at 100,000  g
for 1 h at 4°C. The supernatants were discarded, and pellets were washed by five
sequential suspension and centrifugation steps, each consisting of 100,000 g for
1 h at 4°C with 0.1 M TBS. The 100,000  g pellets were then suspended in 75%
cold ethanol (1 ml). A white precipitate was immediately formed that was
collected by centrifuging this suspension for 5,000 g for 5 min. The supernatant
was then discarded, and the pellet was dried by vacuum centrifugation. The dried
pellet (1 mg) was then dissolved in methanol–1 M HCl at 80°C (18 to 22 h) and
then per-O-trimethylsilylated by treatment with Tri-Sil (Pierce) at 80°C (0.5 h).
Sugar composition was then determined by GC-MS analysis of the resulting
per-O-trimethylsilyl-derivatized monosaccharides on an HP 5890 gas chromato-
graph interfaced to a 5970 MSD mass spectrometer, using a Supelco DB-1
fused-silica capillary column (30 m by 0.25 mm inside diameter). The carbohy-
drate standards used were arabinose, rhamnose, fucose, xylose, glucuronic acid,
galacturonic acid, mannose, galactose, glucose, mannitol, dulcitol, and sorbitol.
Modification of C. neoformans cells for epitope analysis. (i) Proteinase K
digestion. Strains 24067, B3501, and cap67 were incubated with 1 mg/ml pro-
teinase K (Roche, Nutley, NJ) in 100 mM Tris-HCl (pH 8.0) for 3 h at 37°C.
Proteinase K was heat inactivated by boiling samples for 5 min. As a control, cells
not treated with proteinase K were boiled for 5 min.
(ii) Sodium metaperiodate oxidation. Strains 24067, B3501, and cap67 were
incubated with 1 mM or 11 mM sodium metaperiodate (Pierce, Rockford, IL)
overnight at 4°C. The reaction was stopped with ethylene glycol, and the cells
were washed several times in PBS and IF buffer. Periodate concentrations
greater than 10 mM oxidize many sugar residues, such as galactose and mannose
(http://www.piercenet.com/files/1161dh5.pdf).
(iii) DMSO. DMSO removes capsule polysaccharides (4, 14). Strains 24067,
B3501, and cap67 were incubated with in pure DMSO (Sigma, St. Louis, MO) for
1, 3 and 24 h. DMSO was washed with PBS, and cells were prepared for
immunofluorescence.
Proton NMR of GalXM. GalXM was dissolved in D2O, and all NMR exper-
iments were performed at 329 K on a Bruker DRX 600MHz spectrometer
equipped with a 5-mm inverse-triple-resonance probe. 1D proton spectra were
collected with 512 scans of 64 K points over 20 ppm and a total recycle delay of
4 s. The residual water in the spectrum was removed using presaturation of the
HOD signal. Spectra were processed with an exponential line broadening of 1
Hz, and the proton chemical shifts were referenced to internal 3-(trimethylsilyl)
propionate.
Nucleotide sequence accession number. The sequence from scFv D8 has been
submitted to GenBank under accession no. FJ233885.
RESULTS
Generation of serological reagents for the study of GalXM.
Immunization of mice or rats with GalXM elicited no signifi-
cant antibody response (data not shown). To circumvent this
problem we synthesized a GalXM-protein conjugate using the
PA protein from B. anthracis. We then immunized mice and
rats with the conjugate and attempted to make MAbs. Al-
though the PA-polysaccharide conjugate was immunogenic, we
were unable to generate MAbs using either mice or rats be-
cause the hybridomas were unstable. Hence, we hyperimmu-
nized mice and rats and generated polyclonal serum to
GalXM. Specific antibodies in this serum were mostly IgM.
This serum was used for immunofluorescence on C. neofor-
mans strains cap67, B3501, and 24067. Immunofluorescence
revealed a punctate pattern around the cell wall in acapsular
strains, a pattern consistent with prior reports that GalXM is
mostly cell wall associated (32, 33). Encapsulated strains
showed a punctate pattern near or on the edge of the capsule.
3D reconstructions of confocal images produced the same pat-
tern (Fig. 1).
GalXM-deficient mutants confirm specificity of polyclonal
antibody. To ascertain that the polyclonal serum obtained
from GalXM-PA-immunized mice was specific for GalXM, we
tested its reactivity for C. neoformans mutants that made no
GalXM. First, we tested the uge1 and ugt1 mutants that
were constructed in the serotype A background since these
were already available (23). There was no binding to the mu-
tants or to the parental strain KN99. Earlier work demon-
strated that GalXM is not a single molecular entity in serotypes
A, C, and D (16). Hence, we hypothesized that our polyclonal
reagent was GalXM serotype specific since we had raised the
antibody against GalXM from serotype D cap67. Conse-
quently, a GalXM-deficient uge1 mutant in the serotype D
(Jec21) background was constructed and tested. The results
revealed no fluorescence for the uge1 mutant and a positive
signal for the parental strain Jec21, demonstrating the speci-
ficity for GalXM (data not shown).
GalXM is consistent with being vesicle associated. The
punctate fluorescence patterns observed led us to address
whether these pockets were transiently secreted or were bound
to the capsule. Although GXM was found in extracellular
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vesicles (31), no information is available with respect to the
secretion of other capsular components. Due to the apparent
diversity of vesicle morphology, composition, and functionality,
we hypothesized that the punctate pattern observed by immu-
nofluorescence for GalXM suggests that it is exopolysaccha-
ride and thus may be secreted in vesicles. To investigate this
possibility, vesicles were prepared from culture supernatants of
cap67 cells as described previously (31) and analyzed for
monosaccharide components by GC-MS. The most abundant
monosaccharide detected was glucose, which is present in high
concentrations in culture medium. Except for glucose, the only
other monosaccharides detected were galactose, mannose, and
xylose (Table 1), the components of GalXM.
Phage display antibodies against GalXM. Since we were
unable to generate MAbs to GalXM due to hybridoma insta-
bility, we sought an alternative approach employing a phage
display. We first screened a library that expressed scFv anti-
body fragments from chickens immunized with FITC-BSA,
naïve against cryptococcal antigens. After several alternating
rounds of panning using biotinylated immunobilized GalXM
and C. neoformans cells, we obtained several scFvs that pro-
duced punctate immunofluorescence patterns similar to that
observed with GalXM-PA polyclonal serum. However, unlike
the abundant puncta observed with GalXM-PA serum on the
capsule, the scFvs bound at only a few points along the capsule.
As all scFvs appeared to have the same binding pattern, we
concentrated further studies in one single clone, which we
named scFv D8. To investigate whether the polyclonal serum
to GalXM and scFv D8 were binding to the same epitope, we
simultaneously bound both probes to the capsule and found
that they rarely colocalized, implying reactivity with different
epitopes (Fig. 2). To investigate the epitope specificity of scFv
D8, we studied its binding to biochemically modified C. neo-
formans cells using proteinase K, DMSO, and sodium meta-
periodate. Proteinase K, which degrades all proteins, or
DMSO, which partially removes the capsule, had no effect on
the binding of serum or the binding of scFv D8. However,
sodium metaperiodate abrogated the binding of polyclonal
serum, while a stronger punctate pattern was observed using
scFv D8. These results suggest that periodate oxidation is dis-
rupting the GalXM epitopes recognized by the polyclonal se-
rum but allows increases in the number of binding sites to scFv
D8 (Fig. 3).
GalXM is not part of the cell wall since it is not covalently
bound to cell wall glucans (16). Unpublished results by van de
Moer et al. suggested that like MPs GalXM diffuses slowly
through the cell wall, cell membrane, and capsule (16). Three-
dimensional reconstructions of confocal images using scFv
clone D8 in C. neoformans H99 cells revealed a vesiclelike
fluorescence structure projecting from the cell wall. Upon fur-
ther magnification, it appears as if this vesicle-like projection
has pushed through the GXM component and resides on the
surface of capsule (Fig. 4). We also evaluated whether the scFv
D8 reactivity was serotype specific. We tested the reagent with
serotypes A, B, C, D, and A/D and found that the scFv binds
serotypes A and D but not B and C and A/D (Table 2).
FIG. 1. Indirect immunofluorescence microscopy of C. neoformans
after staining with GalXM-PA polyclonal sera. GalXM hyperimmune
serum was used to analyze the strains 24067, cap67, and its parent
strain, B3501. (Top panels) Merged bright-field and fluorescence im-
ages for strains 24067 and B3501 cells. Punctate fluorescence is ob-
served for GalXM (green). The scale bar is 10 m. (Lower left panel)
Merged images of bright-field and fluorescence images for strain
cap67. (Lower right panel) Three-dimensional reconstructions from
Z-series stacks of cap67 cells. Green, GalXM; red, GXM; blue, cal-
cofluor white, which stains cell wall chitins. The scale bar is 5 m.
TABLE 1. Glycosyl composition analysis of extracellular vesicles
produced by cap67 cellsa
Glycosyl residue Mass (g)
Arabinose ........................................................................................NDb
Ribose ..............................................................................................ND
Rhamnose........................................................................................ND
Fucose ..............................................................................................ND
Xylose...............................................................................................
Glucuronic acid...............................................................................ND
Galacturonic acid............................................................................ND
Mannose ..........................................................................................
Galactose .........................................................................................
Glucose ............................................................................................
N-Acetylgalactosamine...................................................................ND
N-Acetylglucosamine......................................................................ND
Heptose............................................................................................ND
3-Deoxy-2-manno-2-octulsonic acid .............................................ND
a Positive results () are expressed as function of the relative intensity of the
peaks in the chromatograms. The identification of the sugars detected by GC
(xylose, mannose, galactose, and glucose) was confirmed by MS analysis.
b ND, none detected.
FIG. 2. Indirect immunofluorescence microscopy after binding with
GalXM-PA polyclonal sera and scFv D8 to C. neoformans cells reveals
little colocalization. Indirect immunofluorescence with GalXM-PA poly-
clonal antibody (red) and phage display protein scFv D8 (green) reveals
that both stain the capsule of C. neoformans strain B3501, but only occa-
sional areas suggest colocalization, as implied by the presence of the
yellow area. The cell body was stained with Uvitex 2B, a probe that stains
cell wall chitins (blue). The scale bar is 5 m.
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Proton NMR reveals GalXM variability. Since the poly-
clonal serum was serotype specific, we investigated the possi-
bility of serotype-related structural differences in GalXM by
using NMR. Earlier studies had suggested that that GalXM
may be structurally heterogeneous since its galactose, man-
nose, and xylose components are linked in 15 different ways
(16). The biochemical complexity of that data suggested that
the purified GalXM fractions could be part of a composite of
several closely related antigens (16). Since our polyclonal an-
tibody did not bind to the serotype A strains, we isolated
GalXM from cap67 (serotype D) and compared it to GalXM
extracted from two cap59 mutants derived from the serotype A
background. Proton NMR revealed subtle differences among
the different GalXM molecules on the anomeric region of the
located between 5.4 and 4.3 ppm (Fig. 5). The results are
consistent with fine structural differences in the GalXM mol-
ecule that could translate into antigenic variability.
GalXM does not colocalize with WGA-binding structures
and capsular lipophilic regions. Recently Rodrigues et al.
found that wheat germ lectin (WGA) recognized chitin-like
components at opposite poles of C. neoformans cells (30).
Additionally, the structures recognized by WGA were associ-
ated with the cell wall but also visibly projected into the cap-
sular network. The structures recognized by the WGA lectin
FIG. 3. Epitope specificity of GalXM and scFv D8 shown by indi-
rect immunofluorescence microscopy after binding of GalXM-PA sera
and scFv D8 to modified C. neoformans cells. The y axis shows strains
B3501 and cap67, which were indirectly stained with GalXM hyperim-
mune sera and scFv D8. Along the x axis, cells were chemically mod-
ified as follows: strains were treated with proteinase K treatment for
24 h, DMSO for 24 h, or 11 mM of sodium metaperiodate for 24 h. The
scale bar is 10 m.
FIG. 4. Indirect immunofluorescence microscopy after binding of
MAb to GXM and scFv D8 to C. neoformans strain H99. scFv D8 (green)
shows a vesicle-like structure emerging from the capsule. GXM was de-
tected with MAb 18B7 (red), and the cell wall was detected with cal-
cofluor (blue). The right panel is a magnification of the emerging vesicle.
The scale bar is 5 m. The images are 3D reconstructions using Voxx.
TABLE 2. Serotype reactivity with scFv and polyclonal serum
Serotype Strain
Punctate pattern fora:
GalXM-PA scFv D8
A H99  
KN99  
uge1  
ugt1  
B NIH 112  
C NIH 34  
NIH 1343  
D B3501  
cap67  
24067  
Jec21  
uge1  
A/D MAS92-203  
a GalXM-PA polyclonal serum and scFv D8 were tested with different sero-
types of C. neoformans. , positive reactivity by immunofluorescence; , no
fluorescence detected.
FIG. 5. Proton NMR of GalXM. (A) Proton NMR for GalXM of
C. neoformans strains cap59 and cap67. (B) The lower panel shows
peak differences when the cap67 spectrum is subtracted from the cap59
spectra. Upward peaks show differences in cap59, while downward
peaks show differences in cap67.
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appeared as round or hook-like projections that formed an
interface between the capsule and bud necks (30). Costaining
with GalXM-PA serum and fluorescent WGA revealed that
the polyclonal serum and lectin fluorescence did not colocalize
(Fig. 6). We also evaluated colocalization of the polyclonal
serum and a highly lipophilic carbocyanine dye, DiI, which
binds to the capsule in a punctate pattern (Eisenman et al.,
submitted for publication). The results revealed that some
GalXM puncta colocalized with DiI, possibly reflecting
GalXM release through vesicles. During these colocalization
studies, we noticed accumulation of the polyclonal serum
around budding cells. We also noted that for budding C. neo-
formans cells, the formation of a bridge-like structure over the
emergent bud is detected by the GalXM-PA polyclonal serum
using indirect immunofluorescence (Fig. 6).
Association of GalXM with daughter cells. Given that the
GalXM-PA polyclonal sera bound strongly to buds, we evaluated
the relative binding of this reagent to mother and daughter cells.
To differentiate between them, cryptococcal cell wall was labeled
with sulfo-NHS-LC-biotin, whereby the biotin covalently binds to
the cell wall and does not segregate to new buds. Hence, the
mother cell stains with the Texas red-labeled streptavidin,
whereas the nascent budding cells do not. Using this labeling
protocol, we consistently found that daughter cells preferentially
bound more GalXM-PA serum, implying the presence of GalXM
on the nascent polysaccharide capsules (Fig. 7).
DISCUSSION
Early attempts to generate a reagent to study GalXM in the
capsule partially succeeded with the generation of CN6, a MAb
of the IgM isotype. This antibody was generated against
GalXM using spheroplast lysate (33). CN6 provided insights
that GalXM was near the cell wall, but apart from one publi-
cation (33), no additional studies were reported with encapsu-
lated cells. Unfortunately, this antibody is no longer available
(33). Given a revival of interest in GalXM, we sought to de-
velop new serological reagents to localize this polysaccharide
in the capsule. We were unable to make MAbs due to the
toxicity of GalXM (unpublished) but did obtain a hyperim-
mune serum to a GalXM-PA conjugate that was confirmed to
bind GalXM. We also generated a synthetic antibody, scFv D8,
to an unknown oxidized carbohydrate epitope that illustrates
the antigenic complexity of the capsule. Using these reagents,
we have established the location of GalXM in the capsule,
associated GalXM secretion with vesicles, and associated
GalXM in the nascent capsules of daughter cells, suggesting a
possible role in budding.
We solved the problem of poor immunogenicity by generat-
ing a glycoconjugate of GalXM using a protein carrier, PA
from Bacillus anthracis. Protein conjugation is a well-known
approach to increase the immunogenicity of polysaccharide
antigens. This approach was successfully used to generate an-
tibodies to GXM by creating a conjugate with tetanus toxoid
(11). Immunofluorescence studies revealed that GalXM was
located on the outer edge of the capsule in encapsulated
strains and near the cell wall in acapsular strains. We also
observed that the pattern of binding was punctate.
To establish the specificity of the GalXM-PA polyclonal
serum for GalXM, we investigated its reactivity with the
GalXM-deficient uge1 and ugt1 mutants that were gener-
ated in a serotype A background. The results revealed no
binding of GalXM-PA hyperimmune sera to parent strain
KN99 or to the mutants (23). Since this result implied the
possibility of serotype-related differences in GalXM structure,
we generated a uge1 strain in the serotype D background of
Jec21. The results revealed that the polyclonal antibody bound
parent strain Jec21 but not the uge1 strain. Based on this
result, we concluded that the GalXM-PA hyperimmune serum
is specific for serotype D GalXM. This specificity could reflect
the fact that the GalXM used in the conjugate was obtained
from C. neoformans var. neoformans cap67.
These small discrete pockets observed by immunofluores-
ence led us hypothesize that GalXM may be potentially deliv-
ered in vesicles. Vesicle preparations of cap67 revealed that,
FIG. 6. GalXM colocalization with WGA-binding molecules and capsu-
lar lipophilic regions.C. neoformans strain B3501 was used in all panels. (Top
left panel) Fluorescence of GalXM (green) and WGA (red) shows no colo-
calization. The scale is 10 m. (Top right panel) Merged bright-field and
fluorescence images with GalXM (green) and lipophilic stain DiI (red) show
some colocalization. The scale bar is 5m. (Lower left panel) Merged bright-
field and fluorescence images. GalXM hyperimmune sera (green) detects
capsule location overlying the beginning of budding. (Right) Voxx 3D recon-
struction of the fluorescent image in the left panel of GalXM (green) and
GXM (red). The scale bar is 5 m for both lower panels.
FIG. 7. GalXM association with daughter cells. (Left panel) Indi-
rect immunofluorescence confocal microscopy using GalXM-PA se-
rum detects accumulation of GalXM in budding cells of B3501. This
image is the green channel only of the Z-stack shown in the upper right
panel of Fig. 6. The scale bar is 5 m. (Right panel) Immunofluores-
cence using biotin-streptavidin-Texas red was used to discriminate
between mother and bud cells. GalXM (green) is predominantly
around the daughter cell. The scale bar is 10 m.
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except for glucose, which came probably from the culture me-
dia, the only monosaccharides detected were galactose, man-
nose, and xylose, the components that make up GalXM. Al-
though these results do not conclusively establish that GalXM
is secreted in vesicles, they are consistent with the notion that
some GalXM is vesicle associated.
In a second approach to generate specific antibodies to
GalXM by phage display, we inadvertently made scFv antibod-
ies to oxidized polysaccharides. The scFv D8 produced a dif-
fuse punctate pattern around the capsule similar to that ob-
served with GalXM-PA hyperimmune sera. However, the two
probes rarely colocalized, implying that they recognized differ-
ent antigens. We hypothesized that we may have altered the
epitopes on GalXM in the screen that isolated scFv D8, which
employed periodate-modified biotinylated GalXM for phage
display biopanning. Periodate is known to modify the structure
of GalXM such that xylose is completely eliminated and two-
thirds of galactose and mannose residues are oxidized (7). We
did not attempt a phage display technique using nonoxidized
GalXM since there are no other reagents that specifically rec-
ognize the GalXM molecule.
In an attempt to understand the specificity of D8, we treated
C. neoformans cells with proteinase K, DMSO, and sodium
metaperiodate and compared the levels of binding of
GalXM-PA hyperimmune sera and scFv D8. The results
showed that neither proteinase K nor DMSO affected poly-
clonal or scFv D8 binding to C. neoformans cells. In contrast,
periodate significantly decreased the binding of GalXM-PA
hyperimmune sera and increased the binding of scFv D8, con-
sistent with destruction of native GalXM epitopes and enrich-
ment for newly oxidized polysaccharide epitopes. Given that
scFv D8 was isolated by screening on modified GalXM and
taking into account the results of binding to modified C. neo-
formans cells, we tentatively conclude that D8 recognizes a
polysaccharide moiety that is antigenically different from
GalXM or GXM. ELISA experiments with D8 showed low
affinity to GalXM, as well as some binding to GXM (not
shown). Double staining with a MAb to GXM and scFv D8
produced fascinating images of D8-binding material sur-
rounded by GXM consistent with vesicular transport and ex-
port. Hence scFv D8 appears to bind to a yet-unidentified
oxidized GalXM-like material that is in close association with
GXM and may be a new polysaccharide component of the
capsule.
We also tested the serum and scFv D8 with serotypes A, B,
C, D, and A/D and found that the scFvs, like the serum, bind
serotypes A and D, suggesting that they react with polysaccha-
rides from C. neoformans var. grubii and C. neoformans var.
neoformans, respectively. We noticed that both reagents re-
acted more strongly with serotype D. However, neither the
GalXM-PA immune serum nor the scFvs bound to C. neofor-
mans gatii serotypes B and C. Another difference was that,
unlike the polyclonal serum, scFv D8 does not bind to serotype
A/D. Analysis of GalXM from serotype A and D strains by
NMR revealed subtle differences consistent with structural dif-
ferences that could translated into antigenic differences.
Additionally we tested whether the polyclonal antibody was
binding other previously described structures (30) in the cap-
sule such as chitin-like oligomers and lipids. The results re-
vealed that the polyclonal immune sera did not colocalize with
WGA and only partially colocalized with DiI (30). Interest-
ingly, we noted that the GalXM-PA serum stained strongly
nascent capsules around budding cells. We distinguished nas-
cent cells from mother cells by labeling with sulfo-NHS-LC-
biotin, a reagent that covalently binds to the cell wall and does
not segregate to the bud. We confirmed that the polyclonal
antibody detects more GalXM around the daughter bud, sug-
gesting that GalXM might be involved in the structural rear-
rangements of the capsular polysaccharide that accompany
budding. An alternate explanation for the preferential binding
of the polyclonal antibody to the buds is that the capsule over
the buds is less dense, and this may allow for more efficient
antibody penetration.
In summary, we have made two new reagents for the study of
C. neoformans capsular polysaccharides in the form of a hy-
perimmune serum to GalXM and an scFv that binds to oxi-
dized carbohydrates. Using these reagents, we established that
GalXM was found in the C. neoformans capsule in discrete
pockets amid the GXM layers and was abundant in the cap-
sules of nascent buds. Furthermore, isolated vesicle fractions
contained galactose, consistent with secretion of GalXM by
trans-cell-wall vesicular transport, as has been proposed for
GXM (31). Given the association of GalXM with vesicles and
the partial colocalization with DiI, this punctate distribution
could reflect vesicular transport. The strong staining of
GalXM-PA immune sera for the capsules of budding daughter
cells also reflects increased vesicular transport at sites of nas-
cent capsule formation or a role in capsular remodeling. Our
results are most easily interpreted as indicating that GalXM is
primarily an exopolysaccharide, with a possible role in capsule
formation during budding, rather than functioning as a struc-
tural component of mature capsule. Given the strong immu-
nomodulatory activity of GalXM, one is tempted to speculate
that this material is exported for fungal cell defense and could
serve an important role for cryptococcal survival in various
ecologic niches, including mammalian hosts.
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